At Glysantis, we are leveraging the NanoDendrix™ glycogen nanoparticle platform to develop novel cancer therapeutics. We are currently pursuing two parallel strategies, at different phases of discovery and development
Activating the innate immune response in the tumor microenvironment with a TLR-targeting nanoparticle-polymer complex. Potential to enhance standard-of-care chemo- and immunotherapies in solid tumors. Lead candidate GLY-100 at the pre-clinical stage.
Cytotoxin-loaded nanoparticles armed with targeting ligands that recognize tumor-overexpressed receptors. Discovery stage candidate GLY-200.